Press Releases

Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems 1-9-2014
Radius Announces Key Changes to Management Team 1-9-2014
Radius Names Robert Ward President and Chief Executive Officer 12-17-2013
Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis 4-25-2013
Radius Health to Present at BIO Business Forum(R) 4-18-2013
Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug 3-12-2013
Radius Health to Present at Cowen & Company 33rd Annual Health Care Conference in Boston 2-26-2013
Radius Health to Present at BIO CEO & Investor in New York 2-8-2013
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection 1-7-2013
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis 1-3-2013
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis 12-20-2012
Radius Health Withdraws Registration Statement 11-15-2012
Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting 10-12-2012
Radius Initiates Phase 2 Study of BA058-Transdermal for the Treatment of Postmenopausal Osteoporosis 9-27-2012
Radius Health Announces Upcoming Scientific Presentations at ENDO 2012, the Endocrine Society's 94th Annual Meeting 6-22-2012
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer 4-20-2012
Radius Health, Inc. Files Registration Statement for Proposed Public Offering 2-7-2012
Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis 12-21-2011
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing 12-16-2011
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy 12-5-2011
Radius Closes $27.65 Million Second Tranche of Previously Announced Financing 11-23-2011
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5-24-2011
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis 5-24-2011
Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes 6-19-2010
Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis 8-5-2009
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 3-24-2009
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 11-20-2008
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions 6-9-2008
Radius Completes Enrollment of Phase 2 Clinical Trial of BA058 for Osteoporosis 4-2-2008
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes 1-30-2008


Press Releases 2004-2007 >